Opus Genetics reports Q2 2026 results, cites September BEST1 data and LCA5 dosing plan

Opus Genetics, Inc. (Nasdaq: IRD) reported second quarter 2026 financial results and a pipeline update on August 6, 2026.

For OPGx-BEST1, the company said enrollment in Cohort 1 of the Phase 1/2 trial known as BIRD-1 was completed, and 3-month topline data from that cohort is expected during the second week of September 2026, assuming all participants complete their assessments as scheduled.¹

On OPGx-LCA5, Opus said it reached agreement with the FDA on trial design: the registrational Phase 3 trial will evaluate OPGx-LCA5 in eight participants using a six-month run-in period so each participant serves as their own control before treatment in both eyes.¹ The company added that enrollment in the trial was completed, dosing is expected to begin in the fourth quarter of 2026 using drug supply made with the intended commercial manufacturing process, and topline data are expected by the end of 2027.¹

Other programs are also advancing. OPGx-RDH12 is expected to enter the clinic in the fourth quarter of 2026 and is partially funded through a partnership with the RDH12 Alliance.¹ OPGx-MERTK is expected to begin clinical testing at the Cleveland Clinic Abu Dhabi in the first quarter of 2027,¹ and OPGx-RHO is expected to start clinical testing globally in the second half of 2027.¹

On finances, Opus Genetics had cash and cash equivalents of $88.8 million as of June 30, 2026.¹ The company said combined with potential future funding under its note purchase agreement with Oberland Capital Management, its aggregate cash resources are expected to fund operations into 2029, an estimate that excludes any proceeds from callable warrants or future milestone payments.¹ Net loss for the quarter was $8.1 million, compared with $7.4 million a year earlier, or ($0.08) per basic and ($0.14) per diluted share for the quarter ended June 30, 2026, versus a net loss of ($0.12) per basic and diluted share in the same period of 2025.¹